Cargando…

Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer

Agents that target metastasis are important to improve treatment efficacy in patients with breast cancer. Tangeretin, a citrus flavonoid, exhibits antimetastatic effects on breast cancer cells, but its molecular mechanism remains unclear. Tangeretin targets were retrieved from PubChem, whereas metas...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermawan, Adam, Putri, Herwandhani, Hanif, Naufa, Ikawati, Muthi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294962/
https://www.ncbi.nlm.nih.gov/pubmed/34335799
http://dx.doi.org/10.1155/2021/2234554
_version_ 1783725340433055744
author Hermawan, Adam
Putri, Herwandhani
Hanif, Naufa
Ikawati, Muthi
author_facet Hermawan, Adam
Putri, Herwandhani
Hanif, Naufa
Ikawati, Muthi
author_sort Hermawan, Adam
collection PubMed
description Agents that target metastasis are important to improve treatment efficacy in patients with breast cancer. Tangeretin, a citrus flavonoid, exhibits antimetastatic effects on breast cancer cells, but its molecular mechanism remains unclear. Tangeretin targets were retrieved from PubChem, whereas metastatic breast cancer regulatory genes were downloaded from PubMed. In total, 58 genes were identified as potential therapeutic target genes of tangeretin (PTs). GO and KEGG pathway enrichment analyses of PTs were performed using WebGestalt (WEB-based Gene SeT AnaLysis Toolkit). The PPI network was analyzed using STRING-DB v11.0 and visualized by Cytoscape software. Hub genes were selected on the basis of the highest degree score as calculated by the CytoHubba plugin. Genetic alterations of the PTs were analyzed using cBioPortal. The prognostic values of the PTs were evaluated with the Kaplan–Meier plot. The expression of PTs across breast cancer samples was confirmed using GEPIA. The reliability of the PTs in metastatic breast cancer cells was validated using ONCOMINE. Molecular docking was performed to foresee the binding sites of tangeretin with PIK3Cα, MMP9, PTGS2, COX-2, and IKK. GO analysis showed that PTs participate in the biological process of stimulus response, are the cellular components of the nucleus and the membrane, and play molecular roles in enzyme regulation. KEGG pathway enrichment analysis revealed that PTs regulate the PI3K/Akt pathway. Genetic alterations for each target gene were MTOR (3%), NOTCH1 (4%), TP53 (42%), MMP9 (4%), NFKB1 (3%), PIK3CA (32%), PTGS2 (15%), and RELA (5%). The Kaplan–Meier plot showed that patients with low mRNA expression levels of MTOR, TP53, MMP9, NFKB1, PTGS2, and RELA and high expression of PIK3CA had a significantly better prognosis than their counterparts. Further validation of gene expression by using GEPIA revealed that the mRNA expression of MMP9 was significantly higher in breast cancer tissues than in normal tissues, whereas the mRNA expression of PTGS2 showed the opposite. Analysis with ONCOMINE demonstrated that the mRNA expression levels of MMP9 and NFKB1 were significantly higher in metastatic breast cancer cells than in normal tissues. The results of molecular docking analyses revealed the advantage of tangeretin as an inhibitor of PIK3CA, MMP9, PTGS2, and IKK. Tangeretin inhibits metastasis in breast cancer cells by targeting TP53, PTGS2, MMP9, and PIK3CA and regulating the PI3K/Akt signaling pathway. Further investigation is needed to validate the results of this study.
format Online
Article
Text
id pubmed-8294962
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-82949622021-07-31 Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer Hermawan, Adam Putri, Herwandhani Hanif, Naufa Ikawati, Muthi Evid Based Complement Alternat Med Research Article Agents that target metastasis are important to improve treatment efficacy in patients with breast cancer. Tangeretin, a citrus flavonoid, exhibits antimetastatic effects on breast cancer cells, but its molecular mechanism remains unclear. Tangeretin targets were retrieved from PubChem, whereas metastatic breast cancer regulatory genes were downloaded from PubMed. In total, 58 genes were identified as potential therapeutic target genes of tangeretin (PTs). GO and KEGG pathway enrichment analyses of PTs were performed using WebGestalt (WEB-based Gene SeT AnaLysis Toolkit). The PPI network was analyzed using STRING-DB v11.0 and visualized by Cytoscape software. Hub genes were selected on the basis of the highest degree score as calculated by the CytoHubba plugin. Genetic alterations of the PTs were analyzed using cBioPortal. The prognostic values of the PTs were evaluated with the Kaplan–Meier plot. The expression of PTs across breast cancer samples was confirmed using GEPIA. The reliability of the PTs in metastatic breast cancer cells was validated using ONCOMINE. Molecular docking was performed to foresee the binding sites of tangeretin with PIK3Cα, MMP9, PTGS2, COX-2, and IKK. GO analysis showed that PTs participate in the biological process of stimulus response, are the cellular components of the nucleus and the membrane, and play molecular roles in enzyme regulation. KEGG pathway enrichment analysis revealed that PTs regulate the PI3K/Akt pathway. Genetic alterations for each target gene were MTOR (3%), NOTCH1 (4%), TP53 (42%), MMP9 (4%), NFKB1 (3%), PIK3CA (32%), PTGS2 (15%), and RELA (5%). The Kaplan–Meier plot showed that patients with low mRNA expression levels of MTOR, TP53, MMP9, NFKB1, PTGS2, and RELA and high expression of PIK3CA had a significantly better prognosis than their counterparts. Further validation of gene expression by using GEPIA revealed that the mRNA expression of MMP9 was significantly higher in breast cancer tissues than in normal tissues, whereas the mRNA expression of PTGS2 showed the opposite. Analysis with ONCOMINE demonstrated that the mRNA expression levels of MMP9 and NFKB1 were significantly higher in metastatic breast cancer cells than in normal tissues. The results of molecular docking analyses revealed the advantage of tangeretin as an inhibitor of PIK3CA, MMP9, PTGS2, and IKK. Tangeretin inhibits metastasis in breast cancer cells by targeting TP53, PTGS2, MMP9, and PIK3CA and regulating the PI3K/Akt signaling pathway. Further investigation is needed to validate the results of this study. Hindawi 2021-07-13 /pmc/articles/PMC8294962/ /pubmed/34335799 http://dx.doi.org/10.1155/2021/2234554 Text en Copyright © 2021 Adam Hermawan et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Hermawan, Adam
Putri, Herwandhani
Hanif, Naufa
Ikawati, Muthi
Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer
title Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer
title_full Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer
title_fullStr Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer
title_full_unstemmed Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer
title_short Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer
title_sort integrative bioinformatics study of tangeretin potential targets for preventing metastatic breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294962/
https://www.ncbi.nlm.nih.gov/pubmed/34335799
http://dx.doi.org/10.1155/2021/2234554
work_keys_str_mv AT hermawanadam integrativebioinformaticsstudyoftangeretinpotentialtargetsforpreventingmetastaticbreastcancer
AT putriherwandhani integrativebioinformaticsstudyoftangeretinpotentialtargetsforpreventingmetastaticbreastcancer
AT hanifnaufa integrativebioinformaticsstudyoftangeretinpotentialtargetsforpreventingmetastaticbreastcancer
AT ikawatimuthi integrativebioinformaticsstudyoftangeretinpotentialtargetsforpreventingmetastaticbreastcancer